Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1906 1
1913 1
1971 1
1973 1
1980 1
1987 1
1992 1
1993 1
1999 1
2000 1
2004 1
2005 1
2006 1
2008 1
2009 1
2014 1
2016 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. Dubrot J, et al. Among authors: davis tgr. Immunity. 2021 Mar 9;54(3):571-585.e6. doi: 10.1016/j.immuni.2021.01.001. Epub 2021 Jan 25. Immunity. 2021. PMID: 33497609 Free article.
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB. Rutter AR, et al. Among authors: davis tg. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. doi: 10.1124/jpet.114.214155. Epub 2014 Apr 30. J Pharmacol Exp Ther. 2014. PMID: 24784567
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL. Davis TG, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454. Epub 2009 Jun 4. J Pharmacol Exp Ther. 2009. PMID: 19498103
Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
Podolin PL, Bolognese BJ, Carpenter DC, Davis TG, Johanson RA, Fox JH, Long E 3rd, Dong X, Marquis RW, Locastro SM, Terfloth GJ, Kurali E, Peterson JJ, Smith BR, McQueney MS, Yamashita DS, Capper-Spudich EA. Podolin PL, et al. Among authors: davis tg. J Immunol. 2008 Jun 15;180(12):7989-8003. doi: 10.4049/jimmunol.180.12.7989. J Immunol. 2008. PMID: 18523262 Free article.
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.
Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, Roshak AK. Podolin PL, et al. Among authors: davis tg. J Pharmacol Exp Ther. 2005 Jan;312(1):373-81. doi: 10.1124/jpet.104.074484. Epub 2004 Aug 17. J Pharmacol Exp Ther. 2005. PMID: 15316093
17 results